Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TVGN Tevogen Bio Holdings

Post-Mkt 03-05 19:41:14 EST

0.1551

-0.0311

-16.70%

盘后0.1599

+0.0048+3.09%

19:41 EST

High0.1879	Low0.1428	Vol2.35M
Open0.1800	D1 Closing0.1862	Amplitude24.22%
Mkt Cap31.26M	Tradable Cap3.93M	Total Shares201.52M
T/O388.70K	T/O Rate9.26%	Tradable Shares25.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":0.1551,"timestamp":1772744400000,"preClose":0.1862,"halted":0,"volume":2347952,"hourTrading":{"tag":"盘后","latestPrice":0.1599,"preClose":0.1551,"latestTime":"19:41 EST","volume":173885,"amount":27387.6491163,"timestamp":1772757662603,"change":0.0048,"changeRate":0.030948,"amplitude":0.185687},"delay":0,"changeRate":-0.16702470461868968,"floatShares":25361700,"shares":201522282,"eps":-0.188139,"marketStatus":"Post-Mkt","change":-0.0311,"latestTime":"03-05 19:41:14 EST","open":0.18,"high":0.1879,"low":0.1428,"amount":388697.06717055995,"amplitude":0.242213,"askPrice":0.1736,"askSize":100,"bidPrice":0.14,"bidSize":142,"shortable":0,"etf":0,"ttmEps":-0.188139,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772758800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.1862,"preHourTrading":{"tag":"盘前","latestPrice":0.1806,"preClose":0.1862,"latestTime":"09:29 EST","volume":24206,"amount":4428.56564332,"timestamp":1772720999969,"change":-0.0056,"changeRate":-0.030075,"amplitude":0.047261},"postHourTrading":{"tag":"盘后","latestPrice":0.1599,"preClose":0.1551,"latestTime":"19:41 EST","volume":173885,"amount":27387.6491163,"timestamp":1772757662603,"change":0.0048,"changeRate":0.030948,"amplitude":0.185687},"volumeRatio":3.305732},"requestUrl":"/m/hq/s/TVGN/tweets","defaultTab":"tweets","newsList":[{"id":"2617736865","title":"Tevogen signs LOI to evaluate potential acquisition of Apozeal Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2617736865","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617736865?lang=en_us&edition=fundamental","pubTime":"2026-03-06 04:00","pubTimestamp":1772740817,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent to evaluate a potential transaction with Ap...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-signs-loi-to-evaluate-potential-acquisition-of-apozeal-pharmaceutical-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-signs-loi-to-evaluate-potential-acquisition-of-apozeal-pharmaceutical-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2617573809","title":"Tevogen Bio Signs LOI to Evaluate Apozeal Pharmaceutical Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2617573809","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617573809?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:50","pubTimestamp":1772740214,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding letter of intent to evaluate a potential acquisition of Apozeal Pharmaceutical Inc., aiming to expand its Tevogen Generics strategy. Tevogen said Apozeal would bring an established generics platform, including 11 FDA-approved ANDA products for the U.S. market, additional ANDAs awaiting approval, and other generic products in development, subject to due diligence and definitive agreements.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL1JjzSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014021.USD","IE00BGHQF748.EUR","TVGN","LU2095319765.USD","LU2210150020.SGD","BK4588","NDAQ","BK4112","IE00B64PRP62.GBP","BK4585","LU0314104364.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2617573877","title":"Tevogen Bio Holdings Inc - Actively Considering Other Transactions With a Focus on Life Sciences-Related Businesses","url":"https://stock-news.laohu8.com/highlight/detail?id=2617573877","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617573877?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:50","pubTimestamp":1772740200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA6VBZZV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGN","TVGNW"],"gpt_icon":0},{"id":"2616558608","title":"Tevogen Bio Holdings approves 50-for-1 reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2616558608","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616558608?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:01","pubTimestamp":1772629319,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. said its board approved a 1-for-50 reverse stock split after shareholders authorized it on Feb. 19, 2026. The company expects the split to take effect at 12:01 a.m. on March 6, 2026, with shares trading on a split-adjusted basis the same day under the symbol TVGN and a new CUSIP 88165K 200. Tevogen said the move is intended to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement, and fractional shares will be paid in cash.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL3WLLRN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","SG9999014005.SGD","SG9999014039.USD","TVGN","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","NDAQ","IE00B64PRP62.GBP","BK4588"],"gpt_icon":0},{"id":"2616558318","title":"Tevogen Bio Holdings Inc - Approves Reverse Stock Split at 50 for 1 Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2616558318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616558318?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:00","pubTimestamp":1772629203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA5FG3QH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGN","TVGNW"],"gpt_icon":0},{"id":"2616371975","title":"Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2616371975","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616371975?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:02","pubTimestamp":1772571720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 16:02 ET (21:02 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0},{"id":"2614861731","title":"Tevogen signs LoI to evaluate acquisition of contract research organization","url":"https://stock-news.laohu8.com/highlight/detail?id=2614861731","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614861731?lang=en_us&edition=fundamental","pubTime":"2026-02-28 03:25","pubTimestamp":1772220358,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent to evaluate a potential transaction with a ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-signs-loi-to-evaluate-acquisition-of-contract-research-organization-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-signs-loi-to-evaluate-acquisition-of-contract-research-organization-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2614686164","title":"Tevogen Signs LOI to Pursue CRO Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2614686164","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614686164?lang=en_us&edition=fundamental","pubTime":"2026-02-28 03:20","pubTimestamp":1772220020,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding letter of intent to evaluate a potential acquisition of an unnamed global contract research organization, a deal that the company said could expand its clinical development capabilities and add revenue-generating services, subject to due diligence and definitive agreements.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL6FZyvW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","BK4585","SG9999014039.USD","TVGN","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4139","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2614861617","title":"Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization","url":"https://stock-news.laohu8.com/highlight/detail?id=2614861617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614861617?lang=en_us&edition=fundamental","pubTime":"2026-02-28 03:20","pubTimestamp":1772220000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nTUA6Z07NH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"2614020614","title":"BRIEF-Tevogen Signs LOI To Evaluate Potential Acquisition Of Sciometrix","url":"https://stock-news.laohu8.com/highlight/detail?id=2614020614","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614020614?lang=en_us&edition=fundamental","pubTime":"2026-02-27 02:55","pubTimestamp":1772132151,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Signs LOI To Evaluate Potential Acquisition Of SciometrixFeb 26 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN SIGNS LETTER OF INTENT TO EVALUATE POTENTIAL ACQUISITION OF SCIOMETRIX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA5DM9F4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2614502833","title":"Tevogen Signs LOI to Evaluate Sciometrix Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2614502833","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614502833?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:20","pubTimestamp":1772115618,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. has signed a non-binding, non-exclusive letter of intent to evaluate a potential acquisition of privately held Sciometrix Inc., developer of the Clinicus digital care management platform, that would leave Tevogen with a majority voting interest in Sciometrix if completed. Tevogen said it is exploring the deal to add digital care management and remote patient monitoring capabilities and to integrate Clinicus with its Tevogen.AI initiative, subject to due diligence and definitive agreements.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDLGyW34:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","TVGN","LU0314104364.USD","SG9999014013.SGD","SG9999014021.USD","BK4588","SG9999014039.USD","BK4112","SG9999014005.SGD","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","NDAQ"],"gpt_icon":0},{"id":"2614402940","title":"Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and Its Digital Care Management Platform Clinicus","url":"https://stock-news.laohu8.com/highlight/detail?id=2614402940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614402940?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:20","pubTimestamp":1772115600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA5DM9F4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"2614028865","title":"Tevogen Bio Holdings Inc - Acquisition Would Give Tevogen Majority Voting Interest in Sciometrix","url":"https://stock-news.laohu8.com/highlight/detail?id=2614028865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614028865?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:20","pubTimestamp":1772115600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA5DM9F4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2614028807","title":"Tevogen Bio Holdings Inc - Deal Could Make Tevogen Revenue-Generating Healthcare Enterprise","url":"https://stock-news.laohu8.com/highlight/detail?id=2614028807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614028807?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:20","pubTimestamp":1772115600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA5DM9F4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":0},{"id":"2614547490","title":"Tevogen Bio Holdings Inc. Held Special Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2614547490","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614547490?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:01","pubTimestamp":1772056915,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. held a special meeting of stockholders on February 19, 2026. Stockholders approved an amendment to the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan to increase the number of shares available for issuance under the plan, and approved an amendment to the certificate of incorporation to authorize a reverse stock split at a ratio between 1:25 and 1:85, with the exact ratio to be set by the board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 25, 2026, and is solely responsibl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL8Zk4RS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2607102674","title":"Press Release: Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2607102674","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607102674?lang=en_us&edition=fundamental","pubTime":"2026-01-31 04:00","pubTimestamp":1769803200,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Jan. 30, 2026  -- Tevogen   today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets.Any consideration of a special dividend would be subject to the Company's future financial performance, capital requirements, compliance with applicable solvency laws, including under the Delaware General Corporation Law, and final approval by the Board of Directors after a determination that a dividend would be the best use of Company capital at the time. No assurance can be given that a dividend will be declared, nor as to the timing or amount of any such dividend.Further updates will be provided as appropriate and in accordance with applicable disclosure requirements.This press release contains certain forward-looking statements, incl","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4555","BK4604","03160","TVGN","BK4588","BK4139","BK4585","BK4099"],"gpt_icon":0},{"id":"2607532550","title":"Tevogen Bio Ties Long-Term Stock Incentives to Company Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2607532550","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607532550?lang=en_us&edition=fundamental","pubTime":"2026-01-30 03:45","pubTimestamp":1769715913,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. has announced an update to its long-term stock incentive program, modifying it to align awards with defined company milestones, including revenue. The revised program will apply to all employees, officers, directors, and consultants eligible under the company’s long-term incentives plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on January 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL9mX9k3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","BK4112","IE00B3QW5Z07.USD","BK4139","LU0314104364.USD","LU2095319765.USD","NDAQ","SG9999014039.USD","SG9999014021.USD","LU2210149790.SGD","SG9999014013.SGD","TVGN","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2604914945","title":"Tevogen Bio Holdings Inc. Announces Date for Special Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2604914945","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604914945?lang=en_us&edition=fundamental","pubTime":"2026-01-17 06:30","pubTimestamp":1768602631,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLyG0r5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2602272543","title":"Tevogen Bio Expands T Cell Therapy Pipeline and Boosts Manufacturing Capacity","url":"https://stock-news.laohu8.com/highlight/detail?id=2602272543","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602272543?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:00","pubTimestamp":1768226427,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. announced significant scientific and operational milestones achieved in 2025, which were reported during the J.P. Morgan Healthcare Conference. The company advanced its proprietary ExacTcell platform, enhancing laboratory yields and supporting improved consistency and scalability for its cytotoxic T lymphocyte  therapies. Tevogen expanded its CTL pipeline to cover multiple high-value indications, including additional HLA restrictions for its SARS-CoV-2-specific product, Epstein-Barr virus  associated lymphomas, chronic hepatitis B, and HPV-related cancers. These advancements were supported by Tevogen.AI, the company’s analytics division, to aid in target discovery and prioritization. The updates reflect Tevogen's progress toward developing a scalable, multi-program cell therapy platform and establishing in-house GMP manufacturing capabilities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3nbG5F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0265550946.USD","LU0942090050.USD","LU0345770308.USD","LU0320765489.SGD","LU2756315318.SGD","LU0323591593.USD","IE00B1BXHZ80.USD","LU0971096721.USD","LU0211326755.USD","LU1084165304.USD","LU2237443895.HKD","LU0976567544.SGD","LU2430703178.SGD","LU1119994496.HKD","LU1668664300.SGD","LU1917777945.USD","LU2242649171.HKD","LU1064131342.USD","LU1363072403.SGD","IE00BBT3K403.USD","LU2552382132.HKD","LU1366192091.USD","IE0034235303.USD","BK4516","NDAQ","IE00B1XK9C88.USD","LU1496350171.SGD","LU2237443465.HKD","LU0820561818.USD","LU0820562030.AUD","LU0345769631.USD","BK4207","LU0106261372.USD","LU2023250330.USD","LU2746668461.USD","LU0882574139.USD","TVGN","LU1670627923.USD","LU2746668974.SGD","BK4534","LU0203345920.USD","LU2210149790.SGD","IE00BJTD4V19.USD","LU2381873111.SGD","LU1261432733.SGD","BK4585","LU2210150020.SGD","LU1670628061.USD","LU2023250504.SGD","BK4588"],"gpt_icon":0},{"id":"2584134477","title":"Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584134477","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584134477?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:23","pubTimestamp":1763644980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2025 08:23 ET (13:23 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://semperparatusspac.com","stockEarnings":[{"period":"1week","weight":-0.3562},{"period":"1month","weight":-0.3724},{"period":"3month","weight":-0.5585},{"period":"6month","weight":-0.7851},{"period":"1year","weight":-0.8534},{"period":"ytd","weight":-0.4376}],"compareEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.0148},{"period":"3month","weight":0.0011},{"period":"6month","weight":0.0585},{"period":"1year","weight":0.1877},{"period":"ytd","weight":0.0047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.040664},{"month":2,"riseRate":0.6,"avgChangeRate":0.049009},{"month":3,"riseRate":0.4,"avgChangeRate":-0.191914},{"month":4,"riseRate":0.5,"avgChangeRate":-0.189171},{"month":5,"riseRate":0.25,"avgChangeRate":0.008552},{"month":6,"riseRate":0.25,"avgChangeRate":-0.034979},{"month":7,"riseRate":0.5,"avgChangeRate":-0.078575},{"month":8,"riseRate":0.5,"avgChangeRate":-0.064152},{"month":9,"riseRate":0.5,"avgChangeRate":-0.105281},{"month":10,"riseRate":0.75,"avgChangeRate":1.418967},{"month":11,"riseRate":0.5,"avgChangeRate":-0.189646},{"month":12,"riseRate":0.5,"avgChangeRate":-0.111833}],"exchange":"NASDAQ","name":"Tevogen Bio Holdings","nameEN":"Tevogen Bio Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tevogen Bio Holdings(TVGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tevogen Bio Holdings,TVGN,Tevogen Bio Holdings股票,Tevogen Bio Holdings股票老虎,Tevogen Bio Holdings股票老虎国际,Tevogen Bio Holdings行情,Tevogen Bio Holdings股票行情,Tevogen Bio Holdings股价,Tevogen Bio Holdings股市,Tevogen Bio Holdings股票价格,Tevogen Bio Holdings股票交易,Tevogen Bio Holdings股票购买,Tevogen Bio Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tevogen Bio Holdings(TVGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}